Pacira Biosciences (PCRX) Stock
Non-opioid surgical pain relief company with flagship product. Here's the price, business snapshot, and what's worth knowing about Pacira Biosciences in August 2026.
Pacira Pharmaceuticals (PCRX) is a US-based pharmaceutical company focused on non-opioid, long-acting local anaesthetic products for perioperative pain management. Its flagship offering, EXPAREL, is a long-acting bupivacaine formulation used to control postsurgical pain and reduce opioid use. Investors should note the company is commercially established but relatively small by market-cap (around $989m), which can mean greater sensitivity to quarterly results, product adoption trends, and reimbursement dynamics. Key drivers include wider adoption of non-opioid pain management, potential label or formulation extensions, and any pipeline progress. Offsetting factors include competition from generic or alternative pain therapies, pricing and reimbursement pressures, and clinical or regulatory setbacks. As with any pharmaceutical investment, revenues can be lumpy and the share price volatile. This summary is educational and not personal investment advice; always consider how a stock would fit your risk tolerance and investment horizon.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Pacira Pharmaceuticals' stock, with a target price of $34, indicating growth potential.
Financial Health
Pacira Pharmaceuticals is performing well with strong revenue and profit margins, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption and growth
Investors may watch clinical adoption and hospital uptake of long‑acting anaesthetics as a growth signal, though sales can be affected by reimbursement and competition.
Product differentiation
EXPAREL’s long‑acting formulation sets a clear clinical role in perioperative care, but differentiation can be challenged by generics and alternative pain approaches.
Market and risks
Geographic expansion and label updates could expand opportunity, yet regulatory, pricing and surgical volume risks mean outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
